Genetic studies in mice have provided evidence that H-Ras and K-Ras proteins are bioequivalent. However, human tumors display marked differences in the association of RAS oncogenes with tumor type. Thus, to further assess the bioequivalency of oncogenic H-Ras and K-Ras, we replaced the coding region of the murine K-Ras locus with H-Ras G12V oncogene sequences. Germline expression of H-Ras G12V or K-Ras G12V from the K-Ras locus resulted in embryonic lethality. However, expression of these genes in adult mice led to different tumor phenotypes. Whereas H-Ras G12V elicited papillomas and hematopoietic tumors, K-Ras G12V induced lung tumors and gastric lesions. Pulmonary expression of H-Ras G12V created a senescence-like state caused by excessive MAP kinase signaling. Likewise, H-Ras G12V but not K-Ras G12V induced senescence in mouse embryo fibroblasts. Label-free quantitative analysis revealed that minor differences in H-Ras G12V expression levels led to drastically different biological outputs, suggesting that subtle differences in MAP kinase signaling confer nonequivalent functions that influence tumor spectra induced by RAS oncoproteins.
types (9) . Whereas KRAS is frequently mutated in pancreatic, colorectal and lung adenocarcinomas, HRAS oncogenes are found in a limited percentage of tumors from the salivary gland, urinary track, cervix, or skin. On the other hand, NRAS oncogenes are present in melanomas and hematopoietic tumors. As of to date, the molecular basis for this incidence bias is still unresolved (9) .
Mutant RAS genes also induce different phenotypes when expressed in the germline of patients suffering from RASopathies, a series of developmental defects that result from constitutive activation of RAS signaling pathways (10, 11) . Oncogenic mutations in HRAS lead to relatively mild developmental defects in Costello syndrome patients (12, 13) . In contrast, those KRAS mutations present in human tumors have not been found in RASopathy patients, suggesting that such mutations may cause embryonic lethality (14) .
Similar results have been observed in mouse strains carrying genetically engineered Ras mutations. Whereas expression of resident K-Ras oncoproteins in the germline leads to early embryonic death, expression of an endogenous H-Ras oncogene is well tolerated and leads to developmental defects very similar to those observed in Costello patients (15) (16) (17) (18) . Likewise, germline expression of the partially activated K-Ras V14I mutant isoform results in phenotypic defects that closely resemble those of Noonan patients (19) .
Here we provide genetic evidence that the wild-type H-Ras and K-Ras proteins are bioequivalent in spite of their different structural and biological properties. We have also compared the spectrum of tumors elicited upon expression of the H-Ras G12V Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- Ras G12V oncoproteins from the same mouse K-Ras locus. These studies have revealed that these oncoproteins induce a different spectrum of tumors primarily due to differences in the intensity of MAP Kinase signaling that results from subtle differences in their levels of expression.
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MATERIALS AND METHODS
Mouse strains. Generation of K-Ras +/LSLH-RasG12V mice (K HRasV12 ) is described in Supplementary information. KrasKI (8) , HrasKI (8) , H-Ras -/- (5) , K-Ras +/LSLG12Vgeo (K V12 ) (16) and p53 lox/lox (20) genetically engineered strains have been described.
hUBC-CreERT2 21 , Elas-tTA and tetO-Cre transgenic strains have also been reported (21, 22) . Activation of the inducible CreERT2 recombinase was achieved by feeding the mice with a Tmx-containing diet (Harlan Laboratories). For activation of H-Ras G12V and K-Ras G12V expression in lung tissue, mice were infected with Adeno-Cre particles as described (23) . Trametinib (Mekinist ® ) was purchased from Sellek Chemicals and was administered orally daily (1 mg/kg) for 8 weeks. All mice were maintained in a mixed 129Sv/J x C57BL/6j background and housed in a barrier facility according to standards established by the European Union. All animal experiments were approved by the CNIO, the Carlos III Health Institute and the Comunidad de Madrid Ethical Committees and performed in accordance with the ARRIVE (Animal Research: Reporting on In Vivo Experiments) guidelines.
Histopathology, immunohistochemistry and SA β-Gal staining. Tissues were fixed in 10% buffered formalin and embedded in paraffin. Hematoxilin & Eosin (H&E) staining and immunohistochemistry (IHC) analyses were performed on 3 μm paraffin sections. For IHC, the following antibodies were used: pErk1/2 (9101, Cell Signaling Technology), Active Caspase-3 (MAB835, R&D Systems), SPC (AB3786, Abcam), CC10 (T-18, Santa Cruz Biotechnology), CD3e (clone 145-2C11, Abcam). SA β-Gal activity in cultured MEFs as well as in cryo-sections of lungs was detected by X-Gal staining as described previously (24) .
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- Southern and Western blot analysis. Southern blot analysis is described in Supplementary information. Western blot analysis of protein extracts obtained from total lung tissue or MEFs was performed as described (25 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472. CAN-16-2925 the H-Ras G12V cDNA clone and a genomic DNA fragment containing the four H-Ras coding exons resulted in similar expression levels indicating that the H-Ras intronic sequences do not play a significant role in regulating H-Ras expression ( Fig. 2B and C).
For simplicity, the wild-type K-Ras +/+ mice and the targeted K-Ras +/LSLG12Vgeo and K-Ras +/LSLH-RasG12V strains will be referred to hereafter as K + , K V12 and K HRasV12 , respectively.
Previous studies have indicated that expression of a K-Ras G12V oncogene in the mouse germline results in embryonic lethality (16) . In contrast, expression of the H-Ras G12V oncogene, even in homozygosity, is well tolerated during embryonic development (17, 18) . To determine whether this differential effect is an intrinsic property of the K-Ras G12V and H-Ras G12V oncoproteins, we crossed K HRasV12 mice to EIIA-Cre transgenics (26) to express the H-Ras G12V oncoprotein from the K-Ras locus in the germline. These embryos were no longer viable and died right after implantation, a time similar to that observed for embryos expressing an endogenous K-Ras G12V oncoprotein (16) . Hence, the ability of mice, as well as of Costello syndrome patients, to tolerate expression of an oncogenic H-Ras G12V protein during embryonic development is dictated by the expression pattern of the H-Ras locus.
Expression of H-Ras G12V from the K-Ras locus in adult mice.
Next, we explored the oncogenic properties of the K-Ras G12V and H-Ras G12V isoforms expressed from the K-Ras locus in adult mice. To this end, we inserted in the K V12 and K HRasV12 strains a transgene encoding the inducible CreERT2 recombinase under the control of the human ubiquitin C promoter (21). We exposed K V12 ;hUBC-CreERT2 +/T and K HRasV12 ;hUBC-CreERT2 +/T mice to a continuous Tmx diet to ensure efficient recombination of the Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- targeted K-Ras alleles. Under these conditions, K V12 ;hUBC-CreERT2 +/T mice had a median survival of 24 weeks (Fig. 2D ). In agreement with previous studies (27) , these mice displayed multiple lesions in their lungs as well as abundant gastric papillomas ( Fig. 2E ). No other tissue displayed significant alterations at the histopathological level. K HRasV12 ;hUBC-CreERT2 +/T mice submitted to the same Tmx treatment died 4 to 5 weeks earlier (Fig. 2D ). These mice did not develop detectable lesions in either lungs or stomach ( Fig. 2E ) despite expression of the mutant H-Ras G12V protein in these tissues ( Supplementary Fig. S1D ). Instead, they displayed papillomas on their footpads after approximately 2 months of treatment ( Supplementary Fig. S1E ). Moreover, they had enlarged spleens and thymic tumors ( Fig. 3 ). Tmx-treated control K + ;hUBC-CreERT2 +/T mice did not display detectable lesions for up to one year of age. These observations indicate that oncogenic signaling initiated by K-Ras G12V and H-Ras G12V oncoproteins expressed under the same regulatory sequences has substantially different consequences on tumor formation.
Expression of H-Ras G12V from the K-Ras locus in adult mice induces hematopoietic
disorders. Post-mortem characterization of Tmx-treated K HRasV12 ;hUBC-CreERT2 +/T mice at humane endpoint revealed enlarged spleens infiltrated with myeloid cell populations in 100% of the animals ( Fig. 3A and B ). This phenotype was not observed in K V12 ;hUBC-CreERT2 +/T or K + ;hUBC-CreERT2 +/T mice. Flow cytometry analyses of these infiltrates revealed a dramatic expansion of Gr1 + and Gr1 + /CD11b + doublepositive cells indicative of myeloproliferative disease (MPD) ( Fig. 3C and Supplementary Fig. S2A ). This increase in the myeloid cell compartment was accompanied by a concomitant decrease in CD3 + T cells and CD19 + B cells ( Supplementary Fig. S2A ). Analysis of committed progenitors in the bone marrow Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- (BM) of mice exposed to the Tmx diet for three months revealed a significant increase in the common myeloid progenitors (CMPs) (Lin -/IL7Rα -/Sca-1 -/c- and DN2 (CD44 + /CD25 + ) populations ( Supplementary Fig. S3A ). The characteristic hyperactivation of the Notch pathway in T-ALL was also observed as demonstrated by immunostaining of Hes1 (28) ( Supplementary Fig. S3B ). We also detected abundant lymphocyte infiltrates in a variety of organs including lung, liver, kidney and eye ( Supplementary Fig. S3C ). These data indicate that in addition to MPD, most mice expressing the H-Ras G12V oncoprotein from the K-Ras locus also developed T-ALL, a tumor type not induced by the K-Ras G12V isoform.
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Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- H-Ras G12V driven from the K-Ras locus induces pancreatic tumors. Expression of a resident K-Ras G12V oncogene during late embryonic development in pancreatic acinar cells results in pancreatic intraepithelial neoplasias (PanIN lesions) that occasionally progress to pancreatic ductal adenocarcinomas (PDAC) (22) . No such lesions were observed in H-Ras +/G12V or H-Ras G12V/G12V mice in which the H-Ras G12V oncoprotein is expressed from its own locus (17). To determine whether H-Ras G12V could induce pancreatic lesions when expressed from the K-Ras locus, we crossed K HRasV12 mice to Elas-tTA/tetO-Cre transgenic animals known to selectively express Cre recombinase in acinar cells from E16.5 onwards (22) . Analysis of serial pancreatic tissue sections of K HRasV12 ;Elas-tTA/tetO-Cre animals at one year of age revealed the appearance of focal low and high-grade PanIN lesions indistinguishable from those present in K V12 ;Elas-tTA/tetO-Cre mice ( Supplementary Fig. S4A ). However, the number of lesions was significantly lower than in similar mice expressing the K-Ras G12V oncoprotein ( Fig.   4A ).
Loss of the p53 tumor suppressor p53 accelerated tumor formation in K HRasV12 ;Elas-tTA/tetO-Cre animals (22) . These mice died of PDAC tumors although they survived longer than those mice expressing the K-Ras G12V oncoprotein (30 vs. 17 weeks average survival, a 75% increase) ( Fig. 4B and Supplementary Fig. S4A ). Comparative analysis of K HRasV12 ;p53 lox/lox ;Elas-tTA/tetO-Cre and K V12 ;p53 lox/lox ;Elas-tTA/tetO-Cre mice at 10 weeks of age revealed that the H-Ras G12V expressing animals displayed significantly fewer PanIN lesions and PDAC tumors than those expressing K-Ras G12V (Fig. 4C ).
These quantitative differences are likely to be due to a reduction in the number of initiating events since the number of acinar-ductal metaplasias (ADM) was significantly Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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H-Ras G12V failed to induce lung adenocarcinomas due to excessive MAPK signaling. Systemic expression of H-Ras G12V from the K-Ras locus did not yield lung lesions including hyperplasias or benign adenomas. To rule out non-cell autonomous effects, we infected K HRasV12 and K V12 mice with Adeno-Cre particles to selectively induce oncogene expression in lung tissue. Six months after infection, none of the K HRasV12 mice displayed detectable lesions in their lungs, whereas all K V12 animals had developed multiple lesions including lung adenocarcinomas ( Supplementary Fig. S4C and S4D).
Tmx treatment of K V12 ;hUBC-CreERT2 +/T and K HRasV12 ;hUBC-CreERT2 +/T mice for short periods of time allowed us to analyze the immediate events that followed expression of the K-Ras G12V and H-Ras G12V oncoproteins in lung tissue. Four days after Tmx treatment, H-Ras G12V induced phosphorylation of the downstream Erk1/2 kinases (pErk1/2) in over 20% of the cells, whereas expression of K-Ras G12V only resulted in pErk1/2 immunostaining in less than 5% of the cells (Fig. 5A ). Similar results were obtained seven days after treatment. These findings were not due to a differential number of cells expressing the K-Ras G12V and H-Ras G12V oncoproteins since the levels of Cre-mediated recombination in the lungs of K V12 ;hUBC-CreERT2 +/T and K HRasV12 ;hUBC-CreERT2 +/T mice were similar ( Supplementary Fig. S4E and S4F).
More importantly, when mice were analyzed two weeks after Tmx treatment, the number of pErk1/2 expressing cells in the lungs of K HRasV12 mice decreased dramatically whereas those present in K V12 lungs displayed a modest increase (Fig. 5A ). These Research.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- results were further confirmed by Western blot analysis ( Fig. 5B ). These observations were selective for lung cells since we did not observe significantly differential numbers of pErk expressing cells in other tissues with the possible exception of cells in the basal layer of the skin and in the white pulp of the spleen ( Supplementary Fig. S5A ). To determine whether these results were due to differential expression levels of the two mutant proteins, we compared their relative levels of expression in the lungs of K V12 ;hUBC-CreERT2 +/T and K HRasV12 ;hUBC-CreERT2 +/T mice by a label-free quantification approach (29) . This technique allowed us to determine their relative amounts based on the detection of the shared peptide (6-LVVVGAVGVGK-16) in which the underlined residue corresponds to the activating valine ( Supplementary Fig.   S5B ). As illustrated in Fig. 5C , H-Ras G12V is expressed at about 5-fold higher levels than K-Ras G12V . The higher levels of H-Ras G12V expression also resulted in increased levels of total GTP-bound active Ras complexes as determined by RBD pull down assays ( Fig. 5D ).
Next, we examined whether the increased levels of GTP-bound H-Ras G12V may have an effect on the proliferation of H-Ras G12V expressing cells that might prevent the appearance of hyperplastic lesions. To this end, we used the recombinant K-Ras H-RasG12V allele as a molecular marker for the presence of H-Ras G12V expressing lung cells.
Exposure of 4-week old K HRasV12 ;hUBC-CreERT2 +/T mice to a Tmx diet for four weeks resulted in the effective recombination of the K-Ras LSLH-RasG12V allele, thus indicating that a significant fraction of lung cells expressed the H-Ras G12V oncoprotein (Fig. 6A ).
However, when these K HRasV12 ;hUBC-CreERT2 +/T mice were maintained in a diet lacking Tmx for an additional 8 week period, those cells that contained the recombined 6A). These results were selective for lung cells since the K-Ras H-RasG12V recombined allele remains present in other tissues such as thymus, after the 8 week period in the absence of Tmx (Fig. 6A ). To determine whether the disappearance of the lung cells was due to excessive H-Ras G12V signaling, we treated K HRasV12 ;hUBC-CreERT2 +/T mice with a non-limiting dose (1 mg/kg) of Trametinib, a MEK inhibitor known to effectively block MAPK signaling driven by Ras oncogenes (30) . Trametinib was provided during the 8 weeks in which mice were no longer exposed to Tmx. As illustrated in Fig. 6A , these mice retained the K-Ras H-RasG12V recombined allele indicating that expression of the H-Ras G12V oncoprotein was no longer deleterious for lung cells in the presence of the MEK inhibitor.
H-Ras G12V expression in lung cells induces a senescence-like arrest partially
mediated by p53. The disappearance of H-Ras G12V expressing lung cells was not due to apoptosis since we could not detect increased levels of Caspase 3 in the lungs of Tmxtreated K HRasV12 mice ( Supplementary Fig. S5C ). Likewise, we did not detect senescence-associated β-galactosidase (SA-βGal) expression, a standard marker for oncogene-induced senescence (OIS). Yet, we observed the induction of other senescence markers such as p16Ink4a and p19Arf ( Fig. 5B and 6B ). These results suggest that H-Ras G12V expression may induce some sort of non-canonical senescencelike state. Finally, we interrogated whether this phenomenon could be mediated by p53.
To this end, we introduced p53 lox alleles into K V12 and K HRasV12 mice. As illustrated in Supplementary Fig. S6A and S6B, K HRasV12 ;p53 lox/lox mice developed some hyperplasias and occasional adenomas in 30% of the animals, all of which stained positive for type II alveolar cell markers ( Supplementary Fig. S6C ). These results indicate that induction of a senescence-like phenotype in lung tissue by expression of the H-Ras G12V oncoprotein from the K-Ras locus is only partially mediated by p53.
H-Ras G12V expressed from the K-Ras locus induces OIS in mouse embryonic
fibroblasts. Finally, we decided to compare the effect of expressing the K-Ras G12V and H-Ras G12V oncoproteins from the same K-Ras locus in mouse embryonic fibroblasts (MEFs). Previous studies have shown that overexpression of these oncoproteins in MEFs readily induced OIS (31) . However, when they were expressed from their own endogenous promoters, they failed to induce OIS (16, 17) . We induced expression of either K-Ras G12V or H-Ras G12V oncoproteins by infecting immortalized K V12 and K HRasV12 MEFs with Adeno-Cre particles, respectively. As expected, K-Ras G12V expression did not cause significant changes in downstream signaling (Fig. 7A ). In contrast, expression of H-Ras G12V resulted in a sustained increase in the phosphorylation of the downstream substrates pErk and pAkt ( Fig. 7A ). Moreover, whereas K-Ras G12V expression had no detectable effects on proliferation, expression of H-Ras G12V effectively induced OIS leading to complete cessation of cell proliferation and SA-βGal expression ( Fig. 7B and C) .
H-Ras G12V expressing MEFs displayed increased levels of p53 (Fig. 7A ). Yet, efficient depletion of p53 by small-hairpin RNAs had no effect on cell cycle arrest or induction of senescence, indicating that abrogation of p53 expression was not sufficient to overcome H-Ras G12V -induced OIS ( Supplementary Fig. S7A-C) . Likewise, we observed no significant increase in the expression levels of p16INK4a. However, ectopic expression adenoviral E1A, an oncoprotein known to target the p53 and Rb pathways (32), we were able to bypass OIS and restored efficient proliferation of MEFs (Fig. 7B Research.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- and C and Supplementary Fig. S7D ). Furthermore, E1A cooperated with H-Ras G12V , but not with K-Ras G12V , to transform immortal MEFs (Figs. 7D and Supplementary Fig.   S7E ). In an effort to provide a mechanistic explanation for the dramatic differential effects induced by the K-Ras G12V versus the H-Ras G12V oncoproteins when expressed from the same locus, we established their relative levels of expression using label-free quantification techniques. As illustrated in Fig. 7E , H-Ras G12V was more efficiently expressed (about 2.5-fold) than K-Ras G12V .
To determine whether these minor differences might be responsible for the drastically differential outputs, we decided to explore how differential expression levels of the same oncoprotein, H-Ras G12V , affected the biological behavior of MEFs. Whereas H-Ras G12V expressed from its own promoter had no effect of MEF properties including immortalization, proliferation or senescence (17), H-Ras G12V expression from the K-Ras promoter in K HRasV12 led to rapid OIS ( Fig. 7B and C) . Western blot analysis revealed that the amount of H-Ras protein (both H-Ras and H-Ras G12V ) in K HRasV12 MEFs was 3 fold higher than in H-Ras G12V/G12V MEFs (Fig. 7F ). Since K HRasV12 MEFs also express a wild-type H-Ras protein from its endogenous locus, the amount of H-Ras G12V expressed from the K-Ras locus in K HRasV12 MEFs compared to that expressed from its own locus in H-Ras G12V/G12V MEFs is a mere 2-fold higher (1.9±0.7) than that expressed from its own locus. These observations establish that relatively subtle increases in the levels of The intense focus on RAS biology is due, at least in part, to their involvement in human cancer. Over the years, scientists have been baffled by the distinct incidence of the various RAS oncogenes in tumors (9) . In an attempt to shed some light on this issue, we expanded the early work of Potenza et al. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- strain, K HRasV12 , that expresses the H-Ras G12V oncoprotein from the endogenous K-Ras locus. Germline expression of H-Ras G12V from its own locus had no significant effect on embryonic development. Yet, these animals displayed facial and cardiovascular defects reminiscent of patients with Costello syndrome (17, 18) . However, germline expression of H-Ras G12V from the endogenous K-Ras locus led to early embryonic death at a time similar to that observed for embryos expressing an endogenous K-Ras G12V oncoprotein (16) . Thus, expression of K-Ras and H-Ras oncoproteins from the K-Ras locus is equally deleterious for embryonic development. These observations illustrate that the viability of H-Ras +/G12V and H-Ras G12V/G12V mice must be due to a more restricted pattern of expression, lower expression levels or a combination of both (17, 18) .
Expression of K-Ras G12V in embryonic acinar cells resulted in the formation of low and high-grade PanIN lesions and occasional PDAC tumors (24). Expression of the H-
Ras G12V oncoprotein from the K-Ras locus also resulted in the formation of low and high-grade PanIN lesions albeit at lower frequencies, with no detectable PDAC tumors, at least by one year of age. Whether the high-grade PanINs will eventually progress to yield PDAC tumors in older animals remains to be determined. Recent studies have indicated that K-Ras G12V but not H-Ras G12V promotes tumor formation by suppressing non-canonical Wnt signaling (33) . This property was used to repress the transforming activity of K-Ras G12V in pancreatic xenograft tumor models with prostratin, a PKC activator (33) . It will be interesting to explore whether this natural product has differential activity in pancreatic lesions driven by K-Ras G12V and H-Ras G12V
oncoproteins.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- Ubiquitous expression of H-Ras G12V in adult K HRasV12 mice led to a variety of tumors, mainly papillomas and hematopoietic malignancies. More importantly, the pattern of tumors observed in these mice was significantly different to that present in K V12 animals, thus indicating that H-Ras G12V and K-Ras G12V oncoproteins have different transforming capabilities in different tissues. Tmx-treated adult K HRasV12 ;hUBC-CreERT2 +/T mice developed hematological malignancies not observed in K V12 ;hUBC-CreERT2 +/T animals, including MPD, a disease that resulted from expansion of the CMP population, as well as T-ALL. Previous studies have reported that expression of a resident K-Ras G12D oncogene in the hematopoietic compartment caused fatal MPD (34, 35) as well as T-ALL upon BM transplantation (36) . In these studies, however, K-Ras G12D expression was induced by an Mx1-Cre transgene known to express low levels of Cre recombinase activity during embryonic development. Thus, it is possible that these different results might be due to the differential susceptibility of embryonic hematopoietic precursors to K-Ras oncoproteins.
On the contrary, some tissues are susceptible to K-Ras G12V , but not to H-Ras G12Vinduced neoplastic lesions such as the lung alveoli and the stomach epithelium. The lack of lung tumors in K HRasV12 mice appears to be a consequence of overactivation of the Thus providing further evidence that the senescent-like state of these H-Ras G12V expressing lung cells was due to excessive MAPK signaling.
It has been proposed that the abundance of Ras isoforms can be affected by differences in protein translation efficiency (37) . K-Ras mRNA is less efficiently translated than H-Ras due to the preferential usage of rare codons (37) . Germline replacement of rare codons in the K-Ras locus resulted in mice that expressed higher levels of K-Ras proteins (38) . Interestingly, these mice displayed increased resistance to urethanemediated carcinogenesis, suggesting that increased levels of K-Ras oncoproteins had adverse effects on lung tumorigenesis (38) . Whether these observations were due to the induction of a senescent-like state as described here for the H-Ras G12V oncoprotein, remains to be determined. Precise quantitative analysis of the relative amounts of H-Ras G12V and K-Ras G12V proteins in lung tissue revealed that H-Ras G12V was present at 5fold higher levels than K-Ras G12V . Thus, it is possible that these oncoproteins may have similar signaling properties and their differential effects in lung tissue could be primarily due to quantitative differences in their levels of expression. Whether the differential results obtained in hematopoietic cells in which only H-Ras G12V Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472.CAN- of inducing tumors is also due to quantitative differences remains to be determined. For instance, it is possible that the hematopoietic precursors responsible for initiating MPD and T-ALL may require higher levels of MAP kinase signaling such as those provided by H-Ras G12V expression. Yet, at this time, we cannot rule out that the H-Ras G12V and K-Ras G12V oncoproteins may utilize differential signaling pathways in these hematopoietic cells.
Previous studies have illustrated the presence of H-Ras oncogenes in lung tumors of HrasKI mice exposed to urethane (39) . Indeed, these mice developed more lung tumors than wild-type animals exposed to the same carcinogenic insult, a result attributed to the frequent activation of H-Ras oncogenes (39) . This apparent conundrum could be explained by the presence of lower levels of H-Ras protein in HrasKI mice. Indeed, HrasKI is a chimeric allele made of H-Ras and K-Ras sequences that contains K-Rasderived rare codons in two of the four coding exons. This fact may result in limited translation efficiency (9, 36, 37) . Thus, HrasKI mice may express lower levels of H-Ras as compared to those present in K HRasV12 animals that exclusively use H-Ras-derived codons. Alternatively, urethane may induce mutations and/or epigenetic alterations that prevent the development of the senescent-like state induced by H-Ras G12V expression in K HRasV12 mice.
Finally, in vitro studies also provided strong support for a direct relationship between H-Ras G12V and K-Ras G12V induced MAPK signaling and biological output. Expression of a resident K-Ras G12V oncoprotein in primary MEFs led to immediate immortalization bypassing the replication-induced senescence characteristic of wild-type cells (16 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472. CAN-16-2925 leading to complete cessation of cell proliferation and expression of SA-βGal. This senescence phenotype was accompanied by a robust increase in the phosphorylation of Erk1/2 and Akt. Quantitative analysis of the relative levels of expression of the H-Ras G12V and K-Ras G12V oncoproteins in K HRasV12 and K V12 MEFs, respectively, revealed 2.5-fold higher levels of expression of H-Ras G12V . Thus, raising the possibility that differences other than levels of expression may account for the differential biological outputs induced by these oncoproteins. However, comparative analysis of the levels of expression of H-Ras G12V in K HRasV12 MEFs in which induces irreversible OIS versus H-Ras G12V/G12V MEFs in which there are no significant biological changes revealed a meager 2-fold difference in its levels of expression. Thus, minor changes in the levels of expression of the H-Ras G12V oncoprotein can induce significantly different outputs.
These results, taken together, underscore the need to better understand the molecular mechanisms that regulate the intensity of MAPK signaling in order to control the detrimental effects induced by Ras oncoproteins during neoplastic development.
It is difficult to reckon why the wild-type H-Ras and K-Ras isoforms are bioequivalent in spite of their differential properties relating to cellular trafficking, post-translational processing and subcellular localization, whereas their oncogenic counterparts display differential transforming properties. It is conceivable that cells tolerate an ample range of Ras signaling during normal homeostasis providing that the differential signaling intensities between the different Ras isoforms stay below a critical threshold. In Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on November 21, 2016; DOI: 10.1158/0008-5472. CAN-16-2925 senescence to malignant transformation. Finally, it should be noted that our observations do not eliminate the possibility that different oncogenic Ras isoforms may also engage differential signaling pathways. Understanding the differential outputs of H-Ras and K-Ras oncogenes in different cell types will require a more precise knowledge of the molecular mechanisms that control their key effector pathways. 
